Standout Papers

Talquetamab, a T-Cell–Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma 2022 2026 2023 2024317
  1. Talquetamab, a T-Cell–Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma (2022)
    Ajai Chari, Monique C. Minnema et al. New England Journal of Medicine

Citation Impact

47 standout
Sub-graph 1 of 20

Citing Papers

Evolving understanding of autoimmune mechanisms and new therapeutic strategies of autoimmune disorders
2024 Standout
CAR T therapies in multiple myeloma: unleashing the future
2024 Standout
3 intermediate papers

Works of Elham Askari being referenced

Updated results of a phase 1, first-in-human study of talquetamab, a G protein-coupled receptor family C group 5 member D (GPRC5D) × CD3 bispecific antibody, in relapsed/refractory multiple myeloma (MM).
2021
A Phase 1, First-in-Human Study of Talquetamab, a G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) x CD3 Bispecific Antibody, in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM)
2020
and 1 more

Author Peers

Author Infectious Diseases Oncology RNMI Hematology Molecular Biology Last Decade Papers Cites
Elham Askari 83 326 155 299 233 26 598
Thomas W. Schneider 3 3 93 26 838
C. Liu 2 2 5 1 57 15 332
Joydev Lahiri 26 369
А. Г. Паулиш 2 1 35 324
G. Srinikethan 1 1 54 32 624

All Works

Loading papers...

Rankless by CCL
2026